These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32605684)

  • 1. Beyond the numbers: a critique of quantitative multi-criteria decision analysis.
    DiStefano MJ; Krubiner CB
    Int J Technol Assess Health Care; 2020 Jul; ():1-5. PubMed ID: 32605684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
    Baltussen R; Marsh K; Thokala P; Diaby V; Castro H; Cleemput I; Garau M; Iskrov G; Olyaeemanesh A; Mirelman A; Mobinizadeh M; Morton A; Tringali M; van Til J; Valentim J; Wagner M; Youngkong S; Zah V; Toll A; Jansen M; Bijlmakers L; Oortwijn W; Broekhuizen H
    Value Health; 2019 Nov; 22(11):1283-1288. PubMed ID: 31708065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?
    Baran-Kooiker A; Czech M; Kooiker C
    Front Public Health; 2018; 6():287. PubMed ID: 30374435
    [No Abstract]   [Full Text] [Related]  

  • 5. HTA and MCDA solely or combined? The case of priority-setting in Colombia.
    Castro HE; Moreno-Mattar O; Rivillas JC
    Cost Eff Resour Alloc; 2018; 16(Suppl 1):47. PubMed ID: 30455606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings.
    Marsh K; Thokala P; Youngkong S; Chalkidou K
    Cost Eff Resour Alloc; 2018; 16(Suppl 1):43. PubMed ID: 30455602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
    Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
    Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
    Marsh KD; Sculpher M; Caro JJ; Tervonen T
    Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016.
    Drake JI; de Hart JCT; Monleón C; Toro W; Valentim J
    J Mark Access Health Policy; 2017; 5(1):1360545. PubMed ID: 29081919
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple criteria decision analysis for health technology assessment.
    Thokala P; Duenas A
    Value Health; 2012 Dec; 15(8):1172-81. PubMed ID: 23244821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand.
    Youngkong S; Teerawattananon Y; Tantivess S; Baltussen R
    Health Res Policy Syst; 2012 Feb; 10():6. PubMed ID: 22339981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of relevant information around non-core domains to support Multi-Criteria Decision Analysis (MCDA) for decision making.
    Bayón-Yusta JC; Gutiérrez-Iglesias A; Galnares-Cordero L; Gutiérrez-Ibarluzea I
    GMS Health Innov Technol; 2024; 18():Doc02. PubMed ID: 38655192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis.
    Kolasa K; Zwolinski KM; Zah V; Kaló Z; Lewandowski T
    Orphanet J Rare Dis; 2018 Apr; 13(1):67. PubMed ID: 29703227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.
    Goetghebeur MM; Wagner M; Khoury H; Rindress D; Grégoire JP; Deal C
    Cost Eff Resour Alloc; 2010 Apr; 8():4. PubMed ID: 20377888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
    Guarga L; Badia X; Obach M; Fontanet M; Prat A; Vallano A; Torrent J; Pontes C
    Orphanet J Rare Dis; 2019 Jun; 14(1):157. PubMed ID: 31248421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.
    Miot J; Wagner M; Khoury H; Rindress D; Goetghebeur MM
    Cost Eff Resour Alloc; 2012 Feb; 10(1):2. PubMed ID: 22376143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.
    Campolina AG; Estevez-Diz MDP; Abe JM; de Soárez PC
    PLoS One; 2022; 17(5):e0268584. PubMed ID: 35613115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.